Pfizer Inc. today announced positive topline results from the final prespecified overall survival analysis of the TALAPRO-2 study of TALZENNA ®, an oral poly ADP-ribose polymerase inhibitor, in ...

Pfizer Inc. today announced positive results from the Phase 3 TALAPRO-2 study of TALZENNA ®, an oral poly ADP-ribose polymerase inhibitor, in combination with XTANDI ®, an androgen receptor ...

Pfizer’s prostate cancer therapy Talzenna, when combined with Xtandi, can extend overall survival (OS) by nearly nine months over the standard of care (SoC), according to a Phase III trial.

Xtandi plus leuprolide improved overall survival in prostate cancer patients in the Phase 3 EMBARK trial, with no new safety ...

Pfizer (PFE) reported positive results from a Phase 3 study of Talzenna in combination with Xtandi in the treatment of certain patients with prostate cancer. Read more here.

Despite recent declines, we believe Pfizer stock is a compelling buy right now, with its current price of around $23 likely reflecting existing concerns.

The release of COVID-19 vaccine results days after the 2020 election may have not been a "coincidence" -- and could have been part of an effort by senior Pfizer executives to "deliberately slow ...

TALZENNA in combination with XTANDI is now approved in more than 40 countries globally for patients with mCRPC, indications vary by country. TALZENNA ® (talazoparib) Indication in the U.S.

NEW YORK, October 10, 2024--Pfizer Inc. (NYSE: PFE) today announced positive topline results from the final prespecified overall survival (OS) analysis of the TALAPRO-2 study of TALZENNA ...

Pfizer Inc. announced positive results from the phase 3 TALAPRO-2 study of Talzenna (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with Xtandi (enzalutamide), an ...

Pfizer's TALAPRO-2 study shows Talzenna + Xtandi significantly improves survival in mCRPC patients, with up to a 14-month OS gain in HRR-mutated cases.